Abstract: Objective The aim of this study was to explore the protective effects of erigeron breviscapus,a herbal medicine,on liver and intestinal mucosal barrier functions in rats with hepatic ischemia-reperfusion injury （IRI）. Methods 45 SD rats were randomly divided into control,model and breviscapine-intervened group,and the hepatic and intestinal IRI models were established. The intestinal mucosal SIgA and plasma endotoxin were detected by ELISA,and the inducible nitric oxide synthase （iNOS）,endothelial （eNOS） and total nitric oxide （NO） in intestinal tissues were detected. Serum procalcitonin （PCT）,diamine oxidase （DAO）,TNF-α and IL-1β levels were detected by kits. The Toll-like receptor 4（TLR4） and nuclear factor （NF）-κB were detected by Western blotting. Results The SlgA in model group was significantly lower than that in control group [（0.2±0.1） μg/kg vs. （0.7±0.1） μg/kg,P<0.01],the endotoxin in model group was significantly higher than that in control [（0.8±0.1） EU/ml vs.（0.2±0.1） EU/ml,P<0.01],the iNOS in model group was significantly higher than that in control group [（0.7±0.1）U/g vs.（0.2±0.1） U/g,P<0.01],the eNOS in model group was significantly lower than that in control group [（0.2±0.1） U/g vs. （0.4±0.1） U/g,P<0.01],and the NO in model group was significantly lower than that in control group [（0.2±0.1） μmol/g vs. （0.4±0.0） μmol/g,P<0.01];the PCT in breviscapine-intervened group was significantly higher than that in model group [（5.0±1.2） ng/ml vs.（3.5±0.98） ng/ml,P<0.01],the SlgA in breviscapine intervention group was significantly higher than that in model group [（0.7±0.1） μg/kg vs.（0.2±0.1）μg/kg,P<0.01],while the endotoxin was significantly lower than that in model group [（0.3±0.1） EU/ml vs.（0.8±0.1） EU/ml,P<0.01],the iNOS was significantly lower than that in model group [（0.3±0.1） U/g vs.（0.7±0.1 U/g,P<0.01],the eNOS was significantly higher than that in model group [（0.8±0.2） U/g vs. （0.2±0.1） U/g,P<0.01],and the NO was significantly higher than that in model group[（0.8±0.1） μmol/g vs.（0.2±0.1） μmol/g,P<0.01];the PCT was significantly lower than that in the model group [（3.9±1.0） ng/ml vs. （5.0±1.2） ng/ml,P<0.01],and the DAO was significantly lower than that in the model group [（7.5±1.3） Ku/L vs.（10.5±1.6） Ku/L,P<0.01];the expression of TLR4 and NF-κB in liver tissues and serum TNF-α and IL-1β levels in model group were significantly higher than those in control group （P<0.01）,while they all significantly decreased in breviscapine-intervened group （P<0.01）. Conclusion s Breviscapine might protect hepatic and intestinal mucosal barrier functions in rats with IRI by promoting eNOS/NO expression and down-regulating expression of TLR4 and NF-κB, which might reduce plasma endotoxin.

Key words: Ischemia-reperfusion injury, Liver, Intestinal mucosa, Erigeron breviscapus, Rats